Bioheart, Inc. (OTCQB: BHRT) is an emerging enterprise in the regenerative medicine industry focused on the discovery, development and commercialization of cell-based therapeutics that prevent, treat or cure cardiovascular diseases. The company’s leading product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function in patients with severe heart damage due to a heart attack. In January, Bioheart announced plans to initiate phase III clinical studies of the candidate for the treatment of chronic heart failure in the coming months. Currently, Bioheart is aiming to achieve market approval for MyoCell in 2019.
According to the American Heart Association, approximately 4.9 million Americans are currently living with congestive heart failure, demonstrating the immense market potential for Bioheart’s primary product candidate moving forward. Using muscle stem cells known as myoblasts, MyoCell therapy addresses cardiovascular damage by promoting increased muscle formation in patients’ hearts. In clinical studies, these unique cells have survived in the low-oxygen environment of chronically damaged, scarred heart tissue better than any other cell type, and they can be genetically modified to attract the stem cells of patients in order to assist with the regenerative process.
In addition to the development of cell-based therapeutics, Bioheart promotes revenue through physician and patient-based regenerative medicine training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals and the operation of a cell therapy clinic. In the first quarter of 2015, the company leveraged these products and services to realize an increase in year-over-year revenues of nearly 25 percent, recording $490,000 for the period. In the future, Bioheart’s management team expects these revenue-generating operations to provide necessary funding to support the company’s clinical development activities, as well as general business expenses.
“We continue to advance on our plan and pathway to profitability,” Mike Tomas, president and chief executive officer of Bioheart, stated in a news release. “We remain confident in our abilities and steadfast on our objectives and desire to create positive outcomes for our patients and positive investment outcomes for our shareholders.”
For prospective shareholders, Bioheart represents an intriguing investment opportunity. The company’s unique combination of promising therapeutic candidates and revenue-generating capabilities could provide it with a platform upon which to realize sustainable growth in market share and improved financial results in the years to come.
For more information, visit www.bioheartinc.com
